Loading organizations...
§ Private Profile · Geneva, Geneve, Switzerland
Biopharmaceutical company developing selective NOX inhibitors for chronic fibrotic and inflammatory diseases like diabetic nephropathy.
Genkyotex is a biopharmaceutical company based in Saint-Julien-en-Genevois, France, that develops selective NOX inhibitors targeting oxygen radicals to treat chronic fibrotic and inflammatory diseases. The organization focuses on therapies for orphan conditions such as primary biliary cholangitis and diabetic nephropathy, utilizing its lead dual NOX1/NOX4 inhibitor compound, setanaxib. Prior to its acquisition, the enterprise secured a CHF 18 million Series C venture capital round to advance its clinical trials. In August 2020, Calliditas Therapeutics agreed to acquire the business for approximately €32 million in cash alongside up to €55 million in contingent milestone payments. Throughout its operational history, the corporate leadership team included notable executives such as former chief executive officer Ursula M. Ney, acting chief executive officer Elias Papatheodorou, and board chairman Ernest Loumaye. Genkyotex was originally founded in 2006 by an undisclosed group of founders.
Genkyotex has raised $65.9M across 3 funding rounds.
Genkyotex has raised $65.9M in total across 3 funding rounds.
Genkyotex has raised $65.9M in total across 3 funding rounds.
Genkyotex's investors include BioMedPartners, Claudio Nessi, VI Partners, Eclosion, Vesalius Biocapital, Jesús Martin-Garcia, MP Healthcare Venture Management.
Genkyotex has raised $65.9M across 3 funding rounds. Most recently, it raised $19.7M Series D in January 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 7, 2015 | $19.7M Series D | BioMedPartners, Claudio Nessi, VI Partners | Eclosion, Vesalius Biocapital | Announced |
| Jul 9, 2012 | $25.6M Series C Plus | — | Jesús Martin Garcia, MP Healthcare Venture Management, Vesalius Biocapital | Announced |
| May 25, 2011 | $20.6M Series C | — | Eclosion, MP Healthcare Venture Management, Vesalius Biocapital | Announced |